Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Infectious Diseases,Immunology,Immunology and Allergy
Reference43 articles.
1. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population;Rodger;AIDS,2013
2. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review;Brown;AIDS,2006
3. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients;Cooper;Clin Infect Dis,2010
4. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients;Mocroft;AIDS,2010
5. Association of tenofovir exposure with kidney disease risk in HIV infection;Scherzer;AIDS,2012
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years;Contemporary Clinical Trials;2024-07
2. Dolutegravir induces FOLR1 expression during brain organoid development;Frontiers in Molecular Neuroscience;2024-05-17
3. Efficacy and safety of switching lamivudine-based dual therapies for the maintenance of virologic suppression in adults with HIV-1: a systematic review and network meta-analysis;2023-08-17
4. Treatment Outcomes of Dolutegravir- Versus Efavirenz-Based Highly Active Antiretroviral Therapy Regimens Among Treatment-Naive People Living With HIV;Cureus;2023-06-08
5. An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor–based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1;AIDS Research and Therapy;2023-03-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3